Zacks Investment Research downgraded Pain Therapeutics, Inc. (NASDAQ:PTIE) to Hold in a statement released earlier today.
- Updated: November 29, 2016
Boasting a price of $0.68, Pain Therapeutics, Inc. (NASDAQ:PTIE) traded 0.54% higher on the day. With the last stock price close down -63.28% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. Pain Therapeutics, Inc. has recorded a 50-day average of $0.65 and a two hundred day average of $1.84. Volume of trade was down over the average, with 0 shares of PTIE changing hands under the typical 901,564
Zacks Investment Research has downgraded Pain Therapeutics, Inc. (NASDAQ:PTIE) to Hold in a statement released on 11/30/2016.
On Saturday September 17, 2016, Zacks Investment Research released a statement for Pain Therapeutics, Inc. (NASDAQ:PTIE) bumped up the target price from $0.00 to $2.75 that suggested an upside of 0.08%.
With a total market value of $0, Pain Therapeutics, Inc. has with a one year low of $0.51 and a one year high of $3.00 .
Brief Synopsis About Pain Therapeutics, Inc. (NASDAQ:PTIE)
Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use. The Company has developed REMOXY to make oxycodone difficult to abuse yet provide approximately 12 hours of steady pain relief when used by patients. REMOXY is intended to meet the needs of healthcare prescribing opioid drugs and seeking to minimize the risks of drug diversion, abuse or accidental patient misuse. The Company's drug candidate FENROCK is an abuse-deterrent transdermal pain patch in the pre-Investigational new drug-stage of development. FENROCK is designed to provide pain relief over 72 hours.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.